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vant decision making. According to ASCO-CAP guidelines, 
discordances for central versus local immunohistochemical 
staining of hormone receptors (HR) and human epidermal 
growth factor receptor 2 (HER2) are reported in about 20%, 
major discrepancies in grading for 40% [3–5]. Furthermore, in 
2012, Mirror trialists reported an upgrade of 22% of pN0 
cases to pN1 in central pathology [6]. In the context of these 
data, and because of the lack of consideration of HER2 over-
expression as a prognostic and predictive factor, the AGO 
guidelines have downgraded the available version 8.0 of Adju-
vant! online (LoE 2bB; AGO+/–). Considering immuno-
histochemical tumour markers, Ki-67 is a reliable prognostic 
factor especially after neoadjuvant chemotherapy (NACT)/
short-term endocrine treatment. Data for prediction of chemo-
therapy outcome are less convincing. The committee never-
theless recommends the clinical use of Ki-67 under the pre-
requisite of meticulous quality control (LoE 1aA; AGO+). As 
long as nationwide standardization and quality assurance are 
not implemented, cut-off levels cannot be reliably defined for 
routine use. 
uPA/PAI was tested in prospective trials and is suggested 
as a reliable prognostic marker and a predictive marker for 
the usefulness of chemotherapy in N0 cases (LoE 1aA; 
AGO+).
New molecular tools (mRNA, DNA level) have the 
advantage of higher accuracy, reproducibility and lower inter-
observer variability compared to IHC. To allow for adequate 
evaluation of available molecular markers/genomic signatures, 
Introduction
For the last 12 years, the Breast Committee of the Arbeitsge-
meinschaft Gynäkologische Onkologie (German Gynaeco-
logical Oncology Group, AGO) has been preparing and up-
dating evidence-based recommendations for the diagnosis and 
treatment of patients with early and metastatic breast cancer. 
The AGO Breast Committee consists of 43 gynaecological on-
cologists specialized in breast cancer and interdisciplinary 
members specialized in pathology, radiological diagnostics, 
medical oncology and radiotherapy. The update is performed 
according to documented rules by thoroughly reviewing 
and scoring chapter by chapter the recent publications 
for their scientific validity (Oxford Level of Evidence, LoE; 
www.cebm.net [1]) and clinical relevance (AGO Grades of 
Recommendation; table 1). Here we present the 2013 update 
of these guidelines focussing on the modifications that were 
performed this year. The full version of the update is available 
online as a PDF file in an English and a German version [2].
Prognostic and Predictive Factors
Currently, the indication for adjuvant chemotherapy is mainly 
driven by prognosis and to a much lesser extent by prediction. 
Since the publication of the molecular classification of breast 
cancer, the role of classical pathology and immunohistochem-
istry (IHC) has been questioned as a sole instrument for adju-
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the AGO Breast Committee valued prospective-retrospective 
evidence, generated by retrospective analyses using archived 
tissue from prospective trials, to LoE IB as proposed by 
Simon et al. in 2009 [7]. Validated molecular signatures may 
be used in individual cases in which classical prognostic 
factors provide contradictory results; however, a general 
recommendation cannot be given for lack of prospective data 
(LoE 2bB; AGO+/–). The largest prospective-retrospective 
body of evidence exists for Oncotype DX® (Genomic Health 
Inc., Redwood City, CA, USA) (LoE IB, prognostic and 
predictive for chemotherapy) in HR+/N0–1 breast cancer [8, 
9]. Endopredict® (Sividon Diagnostics GmbH, Cologne, 
Germany) (LoE IB for prognosis) was evaluated in HR-
positive postmenopausal patients receiving endocrine therapy 
only and cannot be used for prediction of chemotherapy 
outcome [10]. Mammaprint® (Agendia BV, Amsterdam, 
Netherlands) has been evaluated in N0–1 breast cancer (LoE 
IIC for prognosis) [11]. Additionally, PAM50, a gene ex-
pression signature which reproduces molecular subtypes (LoE 
IIB for prognosis), will soon be commercially available in 
Germany [12].
Ductal Carcinoma In Situ
About 74,000 women are diagnosed with primary breast 
cancer in Germany every year [13]. This rate has increased 
over the last years after the introduction of a mammography 
screening program in 2006. This high incidence underlines the 
relevance of an interdisciplinary diagnostic and therapeutic 
management. 
For the pretherapeutic assessment of suspicious lesions 
(BIRADS IV), stereotactic core needle biopsy or vacuum-
assisted biopsy are recommended (LoE 2bB; AGO++). If the 
lesion is completely removed in the course of the biopsy, a 
marker clip should be left at the biopsy site to mark the exact 
location of the lesion (LoE 5D; AGO++). Moreover, a clinical 
examination should be performed. 
When planning the type of surgery, it should be considered 
that patients diagnosed with ductal carcinoma in situ (DCIS) 
and a palpable mass have a significantly higher potential for 
occult invasion (26%), multicentricity and local recurrence. 
Breast-conserving surgery (BCS) is often possible, but in the 
case of tumour-free margins of less than 2 mm re-excision is 
recommended (LoE 2C; AGO+). Mastectomy should be 
considered in the case of large lesions (confirmed by multiple 
biopsies) or positive margins after re-excision (LoE 2aB; 
AGO++). When mastectomy is required, a simultaneous 
sentinel node excision (SNE) should be performed, as SNE 
after mastectomy is not feasible if an invasive component is 
diagnosed in the mastectomy tissue (LoE 3bB; AGO+). In the 
case of BCS and a large DCIS (> 5 cm) or DCIS ≥ 2.5 cm of 
high-grade and/or with comedonecrosis, SNE should be 
discussed individually (LoE 3bB; AGO+/–). DCIS in male 
patients should be treated with mastectomy and SNE (LoE 
5D; AGO+).
Regarding radio-oncological aspects, new data confirmed 
that there is no patient subset – not even a low-risk subgroup 
– that does not benefit from radiotherapy after BCS in terms 
of improved local tumour control (LoE 1a) [14]. As for 
radiation therapy after BCS in patients with invasive breast 
cancer, hypofractionated radiotherapy might be as safe and 
effective as normofractionated (i.e. standard) radiotherapy. 
This is now being tested in a randomised phase III study of 
radiodoses and fractionation schedules in non-low-risk DCIS 
of the breast to improve time to recurrence (TROG 07.01; 
www.anzctr.org.au).
Concerning the use of tamoxifen after surgery with or 
without radiotherapy of DCIS, a Cochrane meta-analysis was 
published in 2012 [15]. 2 randomized controlled trials were 
included involving 3,375 women. Tamoxifen reduced the risk 
of recurrence of ipsilateral DCIS (hazard ratio (HR) 0.75; 
95% confidence interval (CI) 0.61–0.92) and contralateral 
DCIS (relative risk (RR) 0.50; 95% CI 0.28–0.87). There was 
a trend towards decreased ipsilateral invasive cancer (HR 
0.79; 95% CI 0.62–1.01) and reduced contralateral invasive 
cancer (RR 0.57; 95% CI 0.39–0.83). The number needed to 
treat to have a protective effect against all breast events was 
15. No reliable number needed to harm could be calculated. 
Moreover, it was not clear how patient characteristics (e.g. 
menopausal status, age and tumour oestrogen receptor (ER) 
status) affected or predicted response to tamoxifen. There was 
no evidence for a difference in mortality (RR 1.11; 95% CI 
0.89–1.39). Therefore tamoxifen is an option after considering 
risk and benefit (LoE 1aA; AGO+).
Neoadjuvant Chemotherapy
In the past year, no practice-changing data concerning NACT 
have been presented. Thus, only minor modifications have 
been made in the 2013 AGO recommendations. In general, 
Table 1. AGO grades of recommendation
++ This investigation or therapeutic intervention is highly beneficial for patients, can be recommended without restriction, and should be performed.
+ This investigation or therapeutic intervention is of limited benefit for patients and can be performed.
+/– This investigation or therapeutic intervention has not shown benefit for patients and may be performed only in individual cases. According to 
current knowledge a general recommendation cannot be given.
– This investigation or therapeutic intervention can be of disadvantage for patients and might not be performed.
–/– This investigation or therapeutic intervention is of clear disadvantage for patients and should be avoided or omitted in any case.
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NACT is a therapy option if similar postoperative adjuvant 
chemotherapy is indicated (LoE 1bA; AGO+). In particular, 
in patient subgroups where pathologic complete response 
(pCR) is associated with improved survival, such as triple-
negative and HER2-positive, NACT (plus targeted therapy) 
should be the preferred therapeutic approach (AGO+). In 
triple-negative breast cancer, platinum salts, appearing 
promising as active agents in BRCA mutation carriers, should 
be given preferably within the context of clinical trials. 
A recent trial failed to demonstrate additional benefit [16]. 
Results from further trials are awaited (e.g. ADAPT, 
GeparSixto). Response-guided treatment has proven to be 
beneficial within the Gepartrio trial [17]. Consequently, in the 
case of response after 2 cycles of DAC (docetaxel, doxo-
rubicin, cyclophosphamide) in HR-positive breast cancer, 
a total of 8 instead of 6 cycles of DAC may be considered 
(LoE 2bC; AGO+). In the case of non-response after 2 cycles 
of DAC, continuation of neoadjuvant systemic therapy with a 
non-cross-resistant regimen, such as 4× NX (vinorelbine and 
capecitabine) may be beneficial (LoE 2bB; AGO+). 
With regard to endocrine neoadjuvant therapy, prognostic 
factors (such as quantitative ER expression, level of Ki-67, 
N status or T status, e.g. PEPI score) can be assessed during 
and after NACT (LoE 1bB; AGO+). 
Indications for mastectomy after NACT are: positive 
margins after repeated excisions (LoE 3bC; AGO++), 
radiotherapy not feasible (LoE 5D; AGO++), and 
inflammatory breast cancer in the case of only clinical CR 
(LoE 2bC; AGO+). In inflammatory breast cancer with pCR 
after NACT, BCS may be discussed with the patient 
(AGO+/–) as an individual option mentioning the scarce data 
base for such an approach. Similarly, multicentric lesions and 
large tumours (cT4a-c) are only relative indications for 
mastectomy after NACT (AGO+/–).
Breast Cancer Surgery – Oncological Aspects
Two studies concerned with the role of sentinel node biopsy 
(SNB) before and after NACT were presented and published 
at the San Antonio Breast Cancer Symposium 2012. The 
German SENTINA trial is a 4-arm prospective multicentre 
cohort study designed to evaluate a specific algorithm for the 
timing of a standardized SNB procedure [18]. In addition to 
the clinical examination, all patients underwent an axillary 
ultrasound before starting NACT. In 20% of clinically node-
positive patients the axillary status was confirmed cyto-
logically or histologically. 1,737 eligible patients from 103 
institutions entered the trial. The SN detection and removal 
rate was 99.1% in clinically node-negative patients who 
underwent SNB prior to NACT. A second SNB after NACT 
and SNB before NACT had a detection rate of only 60.8%. 
For patients with N1 before NACT and N0 after NACT the 
detection rate of SNB was only 80.1%. Taking these results 
into consideration, the AGO committee recommends SNB 
before NACT for patients with clinical and sonographical N0 
(LoE 3bC; AGO+). For patients with N1 before NACT, 
axillary lymphonodectomy is necessary after NACT; SNB is 
not recommended after NACT (LoE 2bB; AGO–).
Despite the results of the SENTINA trial and the AGO 
recommendations, the ACOSOG Z1071 trial [19] shows a 
possible clinical way to reduce the morbidity of axillary 
dissection for patients planned for NACT. 756 patients were 
enrolled in this study. Core biopsy or fine needle aspiration of 
the clinically and sonographically suspicious lymph node 
before the planned NACT was mandatory. Only patients with 
histologically or cytologically proven lymph node metastasis 
were included in the trial. pCR of the lymph node metastases 
was 40%. After NACT, an SNB was performed. The false-
negative rate was only 7.4%. If more than 2 SN were detected 
and removed, the lymph node metastasis was marked with a 
clip after the biopsy, and radiocolloid and additional blue dye 
were used for SN identification. 
For risk evaluation after NACT and selection of patients 
for adjuvant radiotherapy it is important to know the 
pathological lymph node status (ypNsn) after but not before 
the NACT [20]. The ACOSOG trial Z1071 may become the 
basis for the clinical management of axillary lymph node 
metastases in the case of planned NACT.
Oncoplastic and Reconstructive Surgery
Due to the importance of aesthetic aspects in oncologic and 
reconstructive breast surgery, plastic surgical techniques are 
indispensable in preserving the original breast contour or 
even in changing it or, on the other hand if not feasible, in 
reconstructing an aesthetically pleasing breast shape.
Oncoplastic surgery was introduced into the primary 
surgical treatment of breast cancer to enable wider resections 
in BCS with equally aesthetic results (LoE 2bB; AGO++). In 
about 20% of cases, BCS is desired but the tumour/breast 
ratio (TBR) or the location of the tumour are unfavourable so 
that additional oncoplastic procedures such as mastopexy, 
tumour-adapted reduction mammaplasty or volume replace-
ment techniques with flaps, local or distant, are needed [21]. 
In the case of an unfavourable TBR, NACT might improve 
the rate of BCS if adjuvant chemotherapy is indicated 
(AGO+) [22]. On the other hand, the surgeon should not get 
carried away by the possibilities of oncoplastic surgery to 
create wider margins; in the case of low risk (ER+/
progesterone receptor (PR)+/HER2–) or high risk (TN) 
subgroups, more extensive surgery does not necessarily 
improve outcomes [23].
If a mastectomy is necessary, a skin-sparing or nipple-
sparing mastectomy offers the best options for immediate 
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reconstruction with natural looking aesthetic results and 
sufficient oncological safety. A 2010 meta-analysis comparing 
9 studies with 3,739 patients undergoing conventional mastec-
tomy without reconstruction or skin-sparing mastectomy with 
reconstruction showed no significant differences in terms of 
local recurrence rate [24] (LoE 2bB; AGO++). There are 
different options possible to approach the breast gland for 
mastectomy; the periareolar access used to be very popular 
but proved to bear a higher risk of necrosis. In comparison, 
the inferior lateral approach or the incision in the infra-
mammary fold have shown the lowest incidence of 
complications.
In the case of delayed-immediate reconstruction with tissue 
expanders and the necessity of postmastectomy radiotherapy 
(PMRT), it seems advantageous to irradiate the reconstructed 
breast containing a permanent implant instead of an expander 
[25]. On the other hand, after PMRT, the delay of expander-
implant exchange by at least 6 months after completed 
radiotherapy can significantly reduce expander-implant 
failure [26] (LoE 3bC; AGO+).
With the increasing number of immediate implant 
reconstructions after skin-sparing mastectomies, fold 
formation due to the inserted silicone breast implant and 
irregularities in the breast surface are also seen more often. 
This calls for an improvement of implant coverage after 
mastectomy and during reconstruction. Besides the use of 
form-stable anatomical implants, 4 additional techniques or 
new materials can be helpful: autologous tissue, i.e. the 
endoscopically harvested latissimus dorsi flap (LoE 3bC; 
AGO+), use of acellular dermal matrix (ADM) (LoE 3aB; 
AGO+), use of synthetic mesh, and/or use of lipofilling ( LoE 
3bC; AGO+). The rate of complications due to ADM 
decreases with more experience. See in this context various 
retrospective observational studies by experienced users like 
Salzberg [27] with 10-year results using ADM in direct-to-
implant breast reconstructions demonstrating the 
effectiveness and long-term safety of the procedure. In 
competent hands, lipofilling is very effective and has a very 
low complication rate; up to date there is no proof that the 
procedure causes any increased risk of local recurrence. The 
analysis by Seth et al. [28] states that fat grafting after breast 
reconstruction does not adversely affect local tumour 
recurrence or long-term survival follow-up.
Adjuvant Endocrine Treatment  
in Pre- and Postmenopausal Patients
Recent data from large prospective randomized trials showed 
that patients with HR-positive tumours may have a small but 
significant advantage from prolonged endocrine therapy [29]. 
Therefore, the AGO Breast Committee is currently rec-
ommending a treatment duration with TAM of up to 10 years, 
if feasible. Current trials are underway comparing 10 vs. 
15 years of treatment.
Given the small absolute differences that were observed 
for various approaches to give tamoxifen and/or aromatase 
inhibitors alone or in sequence in postmenopausal patients, 
the committee felt that it is more important to motivate 
patients to comply with treatment at full dose for the whole 
treatment period than to stick to one of the endocrine 
approaches. It is preferred to switch to another endocrine 
treatment in the case of toxicities impairing quality of life 
instead of stopping therapy or to lose the compliance of the 
patient. In patients with high risk of early relapse (e.g. node-
positive disease) or in patients with lobular invasive cancers, 
aromatase inhibitors have shown the largest benefit compared 
to tamoxifen and should therefore be considered as first 
treatment approach [30].
In premenopausal patients, the standard endocrine therapy 
is tamoxifen. The use of gonadotropin-releasing hormone 
(GnRH) analogues without chemotherapy is considered as an 
option for young patients with low or intermediate risk of 
relapse and relevant contraindications against tamoxifen, 
who do not receive adjuvant chemotherapy. The addition of 
GnRH analogues to tamoxifen after chemotherapy is not 
supported by the literature [31]. As only 81 patients with age 
≤ 40 years at diagnosis have been randomized to chemo-
therapy+tamoxifen versus chemotherapy+tamoxifen+GnRH 
analogue, this approach is no longer recommended by the 
committee. Treatment duration of tamoxifen can be 
prolonged up to 10 years. There are no data for AI treatment 
longer than 5 years.
Adjuvant Cytotoxic and Targeted Therapy
Recently published trials and meta-analyses actually con-
firmed the AGO treatment recommendations with regard to 
adjuvant cytotoxic and targeted therapy. There were only 
upgrades in the LoE but no clinically relevant modifications. 
In the following, the main strategies in adjuvant therapy of 
early breast cancer are summarized.
Provided that the indication for adjuvant chemotherapy is 
given, anthracycline-based combination chemotherapy is 
regarded as minimum standard treatment (LoE 1aA; 
AGO++). As shown in a meta-analysis, these regimens 
provide an additional reduction in relapse rate (ratio 0.89, 
p = 0.0001) and mortality (ratio 0.84, p < 0.001) compared 
with adjuvant CMF therapy (cyclophosphamide, metho-
trexate, 5-fluorouracil) after 15 years [32.]. In general, by 
adding taxanes, disease-free survival (DFS) and overall 
survival can be further improved (LoE 1aA; AGO++), and 
eventually side effects, particularly cardiotoxicity, can be 
reduced. In trials adding 4 separate cycles of a taxane to a 
fixed anthracycline-based control regimen, breast cancer 
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Adjuvant Bisphosphonates
Several randomized phase III trials have investigated the 
role of bone-modifying therapy with bisphosphonates in 
the adjuvant setting. Data of these trials on whether 
bisphosphonates in addition to adjuvant treatment may 
improve patients’ outcome are conflicting with contradictory 
results leaving this important issue still unanswered. Subset 
analyses of some trials (AZURE, NSABP-B34) suggest that 
the effect of adjuvant bisphosphonates is mainly confined to 
postmenopausal (≥ 50 years, NSABP B34 trial) patients. In 
premenopausal patients of the AZURE trial, non-skeletal 
distant and locoregional recurrence was significantly higher in 
patients treated additionally with zoledronic acid. Based on 
these conflicting data, the use of bisphosphonates as adjuvant 
treatment is not standard of care for patients in general and 
may be considered in postmenopausal patients only (AGO+).
Adjuvant Radiotherapy
Over more than 3 decades, BCS followed by external beam 
whole-breast irradiation (WBI) was established as standard 
of care for early breast cancer. WBI traditionally comprises 
5 weeks (50 Gy in 25 fractions), not including a possible local 
boost irradiation of the tumour bed following WBI. This 
concept has been challenged by approaches focussing on 
more convenient treatment providing a lower total radiation 
dose given in fewer slightly larger fractions and delivered over 
a shorter period of time by use of hypofractionation schedules 
[35–37]. In addition, the necessity of applying WBI in all 
patients was questioned by the idea of partial breast 
irradiation (PBI) [38–41]. The combination of these 
techniques, accelerated partial breast irradiation (APBI), was 
also subject of recently published studies [42].
The 10-year follow-up results for the UK START trials 
(Standardisation of Breast Radiotherapy) were presented at 
the 2012 San Antonio Breast Cancer Symposium [35]. 
Between 1999 and 2002, 4,451 women with completely excised 
invasive breast cancer (T1–3, N0–1, M0) were randomised 
after primary surgery to 3 different techniques of WBI. This 
quality-controlled phase III study revealed that appropriately-
dosed hypofractionated radiotherapy is a safe and effective 
option for patients with early breast cancer. It was shown 
that 41.6 Gy applied in 13 fractions (experimental arm 1) and 
40 Gy in 15 fractions (experimental arm 2) each appear to be 
comparable to 50 Gy in 25 fractions (standard arm). These 
findings were obvious in terms of locoregional tumour control 
and late normal tissue effects. Consequently, the British 
National Institute for Health and Clinical Excellence (NICE) 
introduced the hypofractionated radiotherapy (experimental 
arms 1 and 2) in its guidelines. The concept of hypofractiona-
tion was also proven to be safe and effective in a Canadian 
mortality was further reduced (RR 0.86, p = 0.0005) [32]. A 
meta-analysis revealed significant differences in favour of the 
sequential regimens as compared to anthracycline-taxane-
containing combination regimens [33]. 
In node-positive disease, dose-dense (q2w) adjuvant 
chemotherapeutic schedules may improve the relapse-free 
and overall survival compared to conventional adjuvant 
treatment options (LoE 1aA; AGO++). High-dose chemo-
therapy with autologous stem cell support is not 
recommended as adjuvant treatment in breast cancer (LoE 
1aA; AGO–). The efficacy of CMF versus no chemotherapy 
has been shown in numerous trials with a long-term follow-up 
of now up to 20 years, and has been proven in meta-analyses 
[32]. Therefore, 6 cycles of CMF can be given in patients with 
contraindications for anthracycline- and taxane-containing 
regimens. Still, in patients with a risk profile indicating a need 
for adjuvant chemotherapy, giving CMF is better than giving 
no therapy (LoE 1aA; AGO++).
Capecitabine, gemcitabine, and platinum compounds have 
been investigated in adjuvant trials. So far, none of these drugs 
can be recommended to be included into anthracycline-/
taxane-based regimens. With regard to capecitabine, several 
trials could not demonstrate an additional benefit when adding 
capecitabine to an anthracycline-/taxane-based therapy (LoE 
1aB; AGO+/–). Most of the trials used lower doses of either 
the taxane or capecitabine in order to cope with toxicity.
Considering targeted therapy, all studies that demonstrated 
a benefit for adjuvant trastuzumab in women with HER2-
positive tumours included node-negative and node-positive 
patients, and subgroup analysis showed a benefit for both 
groups of patients. Therefore, trastuzumab-containing 
regimens can be used in node-positive (LoE 1aA; AGO++) as 
well as in node-negative patients whenever chemotherapy is 
considered adequate. Women with node-negative disease, 
additional risk factors, and tumour size > 10 mm will profit 
from trastuzumab (LoE 1aA; AGO++). Moreover limited 
data from adjuvant studies suggests that even patients with 
HER2-positive tumours < 10 mm may gain benefit from 
trastuzumab. Thus, the use of trastuzumab may also be 
considered in smaller tumours (for tumours > 5–10 mm, 
AGO+; for tumours ≤ 5 mm, AGO+/–). In contrast to primary 
systemic therapy, the phase III trials in adjuvant therapy with 
other targeted agents/dual HER2 blockade such as lapatinib 
and pertuzumab are not yet mature (rec ommendation level 
for these 2 compounds: LoE 5D; AGO–). When lapatinib was 
given in delayed adjuvant treatment, DFS did not improve 
significantly (LoE 1bB; AGO–). The BEATRICE trial 
demonstrated no statistically significant improvement in 
invasive DFS with the addition of bevacizumab to adjuvant 
chemotherapy for triple-negative breast cancer (LoE 1bB; 
AGO–/–) [34].
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Cancer of unknown primary (CUP) represents about 5% 
of advanced cancers per year. Therapy for the majority of 
patients in the absence of a specific tumour diagnosis has been 
empiric and relatively ineffective. ER/PR/HER2 as surrogate 
markers for molecular subtypes (AGO++) and molecular 
profiling of tumours are promising techniques to reveal the 
primary site in CUP patients (LoE 2cB; AGO+/–). Systemic 
treatment must be according to the treatment in N+ patients 
(LoE 3aC; AGO++).
Complete local excision with clear margins is the most 
important therapy in the very aggressive angiosarcoma and 
malignant phyllodes tumour (LoE 3aC; AGO++). Axillary 
node dissection is not recommended if lymph nodes are not 
involved clinically (AGO–).
Hormonal Treatment and Alternatives  
in Breast Cancer Survivors
Menopausal symptoms in young patients with breast cancer 
are typically more severe due to the abrupt and rapid decrease 
in oestrogen, and chemotherapy and endocrine treatment 
worsen these symptoms. Evidence that complementary 
therapies are useful is scarce for the majority of them. 
Behavioural modification and yoga may be helpful in mild 
cases of vasomotor symptoms, whereas newer antidepressants 
are promising in moderate to severe cases. Local vaginal 
moisturizers, and in refractory cases, low-dose oestrogen 
creams (estriol), may ameliorate most urogenital symptoms. 
At present, there is insufficient evidence to support any 
natural agent as a viable alternative to hormone therapy to 
treat these symptoms. But the data for the use of hormone 
therapy of postmenopausal symptoms is also controversial 
[43, 44]. Acupuncture may be an option for these women. 
Data from randomized trials shows a significant effect in 
reducing menopausal symptoms [45, 46]. In summary, no 
single agent can ameliorate menopausal symptoms in breast 
cancer survivors. Further study is needed to identify safe and 
effective treatments for menopausal symptoms and to confirm 
their long-term safety in young breast cancer survivors.
large population-based series after 10 years of follow-up for 
patients presenting with grade 3 breast cancer [36]. 
Taken together, the long-term data of these mature, large 
clinical trials confirm the observations of earlier studies. 
Consequently, AGO considers hypofractionated radiotherapy 
as an equal alternative approach (LoE 1aA; AGO++).
Breast Cancer in Specific Situations
Although breast cancer is a relatively common disease, in 
specific situation, the treatments are not standardized and 
cancer-related deaths are higher. Patients younger than 
35 years have a more aggressive tumour biology with high 
mortality rates. They furthermore may be interested in fertility 
counselling. Surgery and systemic treatment do not differ 
from that of early breast cancer in other age groups. Available 
evidence suggests that patients may benefit from tamoxifen 
concerning recurrence and overall survival. There fore, 
tamoxifen must be offered over a period of 5–10 years (LoE 
1bB; AGO++). GnRH agonists during chemotherapy 
treatment appear to protect against chemotherapy-related 
premature ovarian failure in the first year after treatment. 
According to current data, they have no effect on the 
resumption of menses or spontaneous pregnancy rates. 
Therefore, their use is not recommended for fertility 
preservation (LoE 1aA; AGO–). Fertility counselling before 
systemic treatment is mandatory. 
Elderly patients over 65 years represent about 50% of 
breast cancer patients, and their number will rise in the future. 
Today no aspect of the management of older women with 
breast cancer should be driven by chronological age. Geriatric 
assessment and treatment according to standard are 
recommended (LoE 2bB; AGO++). Patients should be closely 
monitored for side effects with prompt intervention. Standard 
treatment must be reduced in frail patients with substantial 
comorbidity or if life expectancy is less than 5 years (LoE 
2bB; AGO++).
Diagnostics, surgery and systemic treatment in male breast 
cancer do not differ from that in women. Screening for 2nd 
malignancies and genetic counselling are recommended 
(AGO++).
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